Immune clues could predict radiotherapy success
NCT ID NCT06826066
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find immune system markers that can predict how well a cancer patient responds to radiotherapy. Researchers will analyze blood samples from 40 adults who have already completed radiotherapy without major side effects. The goal is to personalize future cancer treatments by identifying who will benefit most from radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Henri Mondor, 1 rue Gustave Eiffel,
RECRUITINGCréteil, Île-de-France Region, 94000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple text message transform cancer care?
- Can modern Radiotherapy's late effects be predicted?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva